Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study.

The Journal of pharmacy and pharmacology - 1 Aug 2020

Almurjan Aminah, Macfarlane Hannah, Badhan Raj K S

Abstract excerpt

OBJECTIVE: Paroxetine has been demonstrated to undergo gestation-related reductions in plasma concentrations, to an extent which is dictated by the polymorphic state of CYP 2D6. However, knowledge of appropriate dose titrations is lacking. METHODS: A pharmacokinetic modelling approach was applied to examine gestational changes in trough plasma concentrations for CYP 2D6 phenotypes, followed by necessary dose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computer Simulation
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Dosage Calculations

Share to Models, Biological

Share to Paroxetine

Share to Pharmacogenomic Variants

Share to Pregnancy

Share to Selective Serotonin Reuptake Inhibitors

Source

Identifiers

PMID: 32346890
DOI: 10.1111/jphp.13281

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study.PMID 32346890Read ↗

The application of precision dosing in the use of sertraline throughout pregnancy for poor and ultrarapid metabolizer CYP 2C19 subjects: A virtual clinical trial pharmacokinetics study.Semantic proximity Read ↗

Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy.Semantic proximity Read ↗

Impact of CYP2D6 Genotype on Paroxetine Serum Concentration.Semantic proximity Read ↗

When special populations intersect with drug-drug interactions: Application of physiologically-based pharmacokinetic modeling in pregnant populations.Semantic proximity Read ↗

Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype.Semantic proximity Read ↗

Precision dosing of venlafaxine during pregnancy: a pharmacokinetics modelling approach.Semantic proximity Read ↗

Pharmacogenomic Characterization of Childbearing-Aged Individuals With Mood Disorders in a Tertiary Care Perinatal Mental Health Clinic.Semantic proximity Read ↗

CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.Semantic proximity Read ↗

Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers.Semantic proximity Read ↗

The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants.Semantic proximity Read ↗

Ultrarapid metabolism of clomipramine in a therapy-resistant depressive patient, as confirmed by CYP2 D6 genotyping.Semantic proximity Read ↗

Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.